Latest Femasys News & Updates

See the latest news and media coverage for Femasys. We track all announcements, press releases, and industry mentions in real time, all in one place.

Femasys

Women's reproductive healthcare company

femasys.com

Headquarters: Suwanee, United States
Company type: Public company
Number of employees: 10–60
Industry: Medical Equipment, Supplies & Distribution

Last updated Today

Latest news about Femasys

In short: Femasys secured $30 million in financing and obtained FDA approval for a modular PMA pathway for its FemBloc birth control technology.

Company announcements

Yesterday Femasys

Femasys announces FDA approval of modular PMA pathway for FemBloc

The company advances its non-surgical birth control technology toward US market entry while building commercial infrastructure.

August 7 Femasys

Femasys secures a thirty million dollar private financing round

Nantahala Capital leads the deal, which provides immediate capital and future proceeds tied to specific corporate and market milestones.

June 24 Femasys

Femasys regains compliance with Nasdaq listing requirements

The firm secured official confirmation regarding Listing Rule 5550(a)(2). Leadership will concentrate on commercializing novel fertility treatments and contraceptive devices across global markets.

May 13 Femasys

Femasys expands fertility portfolio in Europe with CE Mark approval for FemHSG Catheter

The catheter complements FemVue for streamlined in-office fertility evaluation and supports procedural efficiency.

Media coverage

Yesterday Yahoo Finance

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential

The U.S. Food and Drug Administration accepted Femasys’ modular premarket approval application for FemBloc, an experimental non-surgical permanent birth control technology.

August 5 RTTNews

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell $0.33, or 11.07 percent, to $2.65 on Friday, after the biomedical company announced a $30 million private placement with accredited...

April 6 Stock Titan

Femasys (NASDAQ: FEMY) targets reverse split and dilutive note, warrant share issuances

Femasys asks holders to approve a 1-for-2 to 1-for-25 reverse stock split and Nasdaq-rule share issuances from convertible notes and warrants that could significantly dilute...

11 November 2025 Femtech Insider

Femasys Gains Momentum with FDA Trial Approval, $12M Financing, and European Expansion | Femtech Insider

Femasys has marked a series of milestones in recent weeks, advancing both its U.S. regulatory pathway and European commercialization for FemBloc, a non-surgical permanent birth...

Never miss news about Femasys

Track Femasys and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Femasys competitors & trending companies

Browse news for competitors to Femasys and other trending companies.